US · Healthcare · Biotechnology
EPS came in at 0.36 against a street estimate of 0.40 — a miss of 10.0%.
Analysts rate Bio-Techne Corp a hold (0 buy, 12 hold, 1 sell out of 13) with an average price target of $70.50.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.94% |
| FMR Inc | 8.16% |
| Vanguard Capital Management, LLC | 6.52% |
| The Goldman Sachs Group Inc | 4.68% |
| HBK INVESTMENTS L P | 4.35% |
| Vanguard Portfolio Management, LLC | 4.15% |
| Morgan Stanley - Brokerage Accounts | 4.07% |
| State Street Corp | 3.81% |
| Document | Date |
|---|---|
| Company announcement · Q2 FY2027 OTHER NOTABLE POINTS • Bio-Techne Corporation filed a Form 8-K dated November 3, 2026. • The filing announces that the company issued a press releas | 2026-11-04 |
| Shareholder vote results · Q1 FY2027 BIO-TECHNE CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Merger Agreement approved by shareholders on September 23, 2026 with 121,929,544 votes | 2026-09-23 |
| Company announcement · Q1 FY2027 BIO-TECHNE CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • Merger Price: $92–$95 per share (proposed by Merck KGaA in Q2 2023; stock trading range | 2026-09-14 |
| Annual report FY2026 BIO-TECHNE CORPORATION – FISCAL YEAR ENDED JUNE 30, 2026 HEADLINE NUMBERS • Company Size: Market capitalization of $9.1 billion as of December 31, 2 | 2026-08-24 |
| Results announced · Q1 FY2027 BIO-TECHNE CORPORATION – FY2026 RESULTS SUMMARY HEADLINE NUMBERS • Full Year Revenue: $1.2 billion, flat versus prior year ($1,215.0M vs $1,219.6M i | 2026-08-12 |
| Material agreement · Q4 FY2026 BIO-TECHNE CORPORATION – FORM 8-K SUMMARY Merger Agreement with Merck KGaA (June 25, 2026) --- HEADLINE NUMBERS • Merger price: $73.00 per share in | 2026-06-26 |
| Reg FD disclosure · Q4 FY2026 BIO-TECHNE CORPORATION FORM 8-K SUMMARY HEADLINE NUMBERS • Acquisition announced: Bio-Techne Corporation has agreed to be acquired by Merck KGaA, Da | 2026-06-25 |
| Quarterly report · Q3 FY2026 BIO-TECHNE CORPORATION - Q1 2026 (9-MONTH) FINANCIAL SUMMARY HEADLINE NUMBERS • Net Sales (9 months ended March 31, 2026): $893,847 thousand ($893.8 | 2026-05-06 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.08 / share ex-date Aug 24, 2026 · pay Aug 28, 2026 | 2026-08-24 |
| Dividend | $0.08 / share ex-date Aug 17, 2026 · pay Aug 28, 2026 | 2026-08-17 |
| Dividend | $0.08 / share ex-date May 18, 2026 · pay May 29, 2026 | 2026-05-18 |
| Dividend | $0.08 / share ex-date Feb 13, 2026 · pay Feb 27, 2026 | 2026-02-13 |
| Dividend | $0.08 / share ex-date Nov 17, 2025 · pay Nov 28, 2025 | 2025-11-17 |
| Announcement | Date |
|---|---|
| Quarterly dividend of $0.08 per share declared, contingent on pending transaction closing Bio-Techne announced a quarterly cash dividend of $0.08 per share for the quarter ended September 30, 2026. It is scheduled to be paid on November 23, 2026, to shareholders who own shares at | 2026-11-04 |
| Shareholders approve merger agreement with Merck KGaA Bio-Techne Corporation held a shareholder meeting on September 23, 2026, to vote on its acquisition by Merck KGaA, a German pharmaceutical company. Shareholders overwhelmingly approved the m | 2026-09-23 |
| Merger agreement with Merck KGaA progressing toward shareholder vote Bio-Techne Corporation disclosed litigation and shareholder demands related to its merger with Merck KGaA, Darmstadt, Germany. A lawsuit filed September 9, 2026 in Minnesota state court clai | 2026-09-14 |
| Agreement and plan of merger with Merck KGaA announced Bio-Techne Corporation is being acquired by Merck KGaA (a German pharmaceutical company) in an all-cash merger. Under the agreement dated June 25, 2026, Bio-Techne shareholders will receive | 2026-06-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bio-Techne Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.